Information Provided By:
Fly News Breaks for September 10, 2018
NBIX
Sep 10, 2018 | 07:53 EDT
As previously reported, Morgan Stanley analyst Jeffrey Hung initiated Neurocrine with an Overweight rating, noting that Ingrezza has grown consistently since launch and he believes higher penetration is still possible. He thinks there's an opportunity for Ingrezza in Tourette Syndrome and sees pipeline candidate NBI-74788 for congenital adrenal hyperplasia possibly contributing to the company's next leg of growth. Hung set a $145 price target on Neurocrine shares.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.